" class="no-js "lang="en-US"> Novo Nordisk - Medtech Alert
Wednesday, March 22, 2023
Novo Nordisk | Pharmtech Focus

Novo Nordisk

About Novo Nordisk

Novo Nordisk

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark.

Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease.

Novo Nordisk employs about 47,000 people in 80 countries and markets its products in around 170 countries.

This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to remove those that are off-topic, abusive or intended to spam.

Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in:

For other customer complaints, please contact us here:

Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industries. Therefore, comments that pertain to legal matters or regulatory issues may be removed.

Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other Linkedin users.

Learn more about our privacy disclaimer and community guidelines here http://www.novonordisk.com/communityguidelines

Related Story

Babyl & Novo Nordisk Partner to Provide an Innovative Approach to Diabetes Awareness and Care in Rwanda

December 1 2022

Babyl, a subsidiary of Babylon, and Novo Nordisk announced today that they have entered an […]

Novo Nordisk and Microsoft Collaborate to Accelerate Drug Discovery and Development Using Big Data and Artificial Intelligence

September 15 2022

Novo Nordisk and Microsoft have entered a new strategic collaboration to combine Microsoft’s computational services, […]

Novo Nordisk to Acquire Forma Therapeutics and Expand Presence in Sickle Cell Disease and Rare Blood Disorders

September 5 2022

Novo Nordisk and Forma Therapeutics, Holdings Inc. (Nasdaq: FMTX) today announced that they have entered […]

Echosens and Novo Nordisk Announce Partnership to Increase Awareness and Advance Early Diagnosis of NASH

June 27 2022

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global […]

Ginkgo Bioworks and Novo Nordisk to Collaborate on Expression Systems for Pharmaceutical Products

June 8 2022

Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a collaboration with Novo […]

Novo Nordisk Receives Fda Approval of Higher-dose Ozempic® 2 Mg Providing Increased Glycemic Control for Adults With Type 2 Diabetes

March 29 2022

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved a […]

Novo Nordisk Expands Research Collaboration in Novel Delivery Technologies for Biologic Medicines

March 10 2022

Novo Nordisk today announced the expansion of its existing research collaboration in oral drug delivery […]

Novo Nordisk to Acquire Dicerna Pharmaceuticals Including the RNAi Research Technology Platform

November 18 2021

Novo Nordisk today announced that it has entered into a definitive agreement to acquire Dicerna […]